Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: Preliminary results

Journal of Neuro-Oncology

Volumn 61, Issue 3, 2003, Pages 267-273

  Chahlavi, Ali ^a   Kanner, Andrew ^a   Peereboom, David ^a   Staugaitis, Susan M ^a   Elson, Paul ^a   Barnett, Gene ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Allelic loss 1p; Chemotherapy; Molecular genetics; Oligodendroglioma; Temozolomide

Indexed keywords

CARMUSTINE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGE; AGED; ALLELE; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENDER; HUMAN; MALE; OLIGODENDROGLIOMA; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TUMOR RECURRENCE; URTICARIA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; DACARBAZINE; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0037298856     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022580610598     Document Type: Article

References (45)

1. Reifengerger G, Kros JM, Burger PC, Louis DN, Collins VP: Oligodendroglioma. In: Kleihues P, Cavenee WK (eds) WHO Classification - Tumours of the Nervous System. IARC Press, Lyon, pp 56-61, 2000
2. Central Brain Tumor Registry of the United States (CBTRUS): 1995 Ref Type: Data File
3. Celli P, Nofrone I, Palma L, Cantore G Fortuna A: Cerebral oligodendroglioma: Prognostic factors and life history. Neurosurgery 35(6): 1018-1034, 1994
4. Ludwig CL, Smith MT, Godfrey AD, Armbrustmacher VW: A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neurol 19(1): 15-21, 1986
5. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD: Oligodendrogliomas: The Mayo Clinic experience. J Neurosurg 76: 428-434, 1992
6. Zulch KJ: Brain Tumors. Their Biology and Pathology, 3rd edn. Springer Verlag, Heidelberg, Germany, 1986
7. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23(4): 360-364, 1988
8. Cairncross JG, Macdonald DR, Ramsay DA: Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 31(1): 78-82, 1992
9. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, Louis DN, Wiestler OD, Von Deimling A: Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54(1): 91-95, 1995
10. Bello MJ, Leone PE, Vaquero J, De Campos JM, Kusak ME, Sarasa JL, Pestana A, Rey JA: Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64(3): 207-210, 1995
11. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP: Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145(5): 1175-1190, 1994
12. Chinot O: Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 28(Suppl 13): 13-18, 2001
13. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90(19): 1473-1479, 1998
14. Rodriguez LA, Levin VA: Does chemotherapy benefit the patient with a central nervous system glioma? Oncology (Huntingt) 1(9): 29-1, 1987
15. Cairncross JG, Laperriere NJ: Low-grade glioma. To treat or not to treat? Arch Neurol 46(11): 1238-1239, 1989
16. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65(2): 287-291, 1992
17. Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ: Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3(7): 1093-1100, 1997
18. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17(9): 2762-2771, 1999.
19. Newlands ES, O'Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG: The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A (13): 2236-2241, 1996
20. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P: Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A(7): 940-942, 1993
21. Van Den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJ, Kros JM, Eskens FA, et al.: Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 57(2): 340-342, 2001
22. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F: Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 19(9): 2449-2455, 2001
23. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5): 588-593, 2000
24. Reifenberger G, Kros J, Burger PC, Louis DN, Collins VP: Anaplastic oligodendroglioma. In: Kleihues P, Cavenee WK (eds) WHO Classification Tumours of the Nervous System. IARC Press, Lyon, pp 62-69, 2000
25. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC Jr, Bullard DE: Clinicopathologic correlations in the oligodendroglioma. Cancer 59(7)L 1345-1352, 1987
26. Chin HW, Hazel JJ, Kim TH, Webster JH: Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer 45(6): 1458-1466, 1980
27. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP: Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neuro-Oncol 34(1): 61-78, 1997
28. Kros JM, Pieterman H, Van Eden CG, Avezaat CJ: Oligodendroglioma: The Rotterdam-Dijkzigt experience. Neurosurgery 34(6): 959-966, 1994
29. Schiffer D, Dutto A, Cavalla P, Bosone I, Chio A, Villani R, Bellotti C: Prognostic factors in oligodendroglioma. Can J Neurol Sci 24(4): 313-319, 1997
30. Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, Macdonald D, Stitt L, Cairncross JG: Pretreatment factors predict overall survival for patients with low-grade glioma: A recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45(4): 923-929, 1999
31. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP: Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neuro-Oncol 34(1): 61-78, 1997
32. Daumas-Duport C, Varlet P, Tucker ML, Beuvon F, Cervera P, Chodkiewicz JP: Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases. J Neuro-Oncol 34(1): 37-59, 1997
33. Shimizu KT, Tran LM, Mark RJ, Selch MT: Management of oligodendrogliomas. Radiology 186: 569-572, 1993
34. Huang F, Kanno H, Yamamoto I, Lin Y, Kubota Y: Correlation of clinical features and telomerase activity in human gliomas. J Neuro-Oncol 43(2): 137-142, 1999
35. Miettinen H, Kononen J, Sallinen P, Alho H, Helen P, Helin H, Kalimo H, Paljarvi L, Isola J, Haapasalo H: CDKN2/p16 predicts survival in oligodendrogliomas: Comparison with astrocytomas. J Neuro-Oncol 41(3): 205-211, 1999
36. Franzini A, Leocata F, Cajola L, Servello D, Allegranza A, Broggi G: Low-grade glial tumors in basal ganglia and thalamus: Natural history and biological reappraisal. Neurosurgery 35(5): 817-820, 1994
37. Heegaard S, Sommer HM, Broholm H, Broendstrup O: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 76(10): 1809-1813, 1995
38. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK: Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 78(5): 1107-1113, 1996
39. Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF, Quagliana JM, Al Sarraf M: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: A Southwest Oncology Group Study. J Neurosurg 78(6): 909-914, 1993
40. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71(8): 2585-2597, 1993
41. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12(10): 2013-2021, 1994
42. Kim L, Hochberg FH, Thronton AF, Harsh GR, Patel H, Finkelstein D, Louis DN: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85(4): 602-607, 1996
43. Olson JD, Riedel E, De Angelis LM: Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54(7): 1442-1448, 2000
44. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B: The treatment of oligodendrogliomas and mixed oligodendroglioma- astrocytomas with PCV chemotherapy. J Neurosurg 76(5): 741-745, 1992
45. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18(3): 636-645, 2000